Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Mixed-drug approach to malaria

Wednesday March 28th, 2018

A drug used to treat parasitic diseases is also effective at controlling mosquitoes, British researchers report today.

Results of a new study suggest that adding high-dose ivermectin to a standard malaria treatment (dihydroartemisinin-piperaquine) in community-wide campaigns such as mass drug administration, could reduce malaria rates by up to 61%.

Furthermore, in areas where only 10% of the population is infected with malaria, adding ivermectin could reduce rate to less than 0.1% for more than six months, say Dr Menno Smit of Liverpool School of Tropical Medicine, UK, and colleagues.

They publish their results today (28 March) in The Lancet Infectious Diseases.

Some 141 adults treated for malaria in Kisumu, Kenya, took part in the randomised trial.

The researchers tested the treatment in laboratory conditions, feeding the blood from patients to mosquitoes. They found that patients treated with low dose ivermectin had blood that killed the creatures four times faster than blood from those treated with placebo.

Dr Smit said: "This is the first study to show the safety and efficacy of multiple high-doses of ivermectin on mosquito mortality. Our results suggest that a 300 microgram per kg dose of ivermectin each day for three days would provide a good balance between efficacy and tolerability."

He adds: "Despite these encouraging findings, further rigorous safety and efficacy trials in younger age groups are needed before high-dose ivermectin can be administered at scale to assess its impact on malaria transmission and human health.

"High-dose ivermectin may also have potential applications in other vector-borne diseases transmitted by mosquitoes including Zika virus, dengue, and West Nile fever, as well as insect- and tick-borne disease like sleeping sickness and Lyme disease.

“Further studies should be done to assess the use of high-dose ivermectin against these insects."

Over 2.5 billion doses of ivermectin have been given across Africa and Latin America to kill parasitic worms, including those that cause river blindness and lymphatic filariasis, and has been shown to be safe, the team states.

Smit, M. et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases 28 March 2018; doi: 10.1016/S1473-3099(18)30163-4


Tags: Pharmaceuticals | UK News | World Health

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)